Skip to main content
Prestige Biologics Co., Ltd. logo

Prestige Biologics Co., Ltd. — Investor Relations & Filings

Ticker · 334970 ISIN · KR7334970001 KO Manufacturing
Open in API
Filings indexed 203 across all filing types
Latest filing 2025-09-26 Declaration of Voting R…
Country KR South Korea
Listing KO 334970

About Prestige Biologics Co., Ltd.

https://prestigebiologics.com/en/

Prestige Biologics is a biopharmaceutical Contract Development and Engineering Manufacturing Organization (CDEMO) that provides end-to-end solutions for the entire lifecycle of a drug, from initial development to commercial production. The company specializes in antibody-based therapeutics and offers a comprehensive suite of services including process development, analytical testing, manufacturing of drug substances and drug products, and secondary packaging for clinical trials. It supports clients through all clinical stages by providing services optimized for their specific needs, utilizing advanced equipment and GMP-compliant facilities.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 96% confidence The document is the formal results of the company’s regular shareholders’ meeting (정기주주총회결과) held on 26 September 2025. It lists resolutions adopted (approval of financial statements, director appointments, charter amendments, etc.) along with voting outcomes. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-09-26 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 93% confidence The document is a statutory notification to the Financial Services Commission/Korea Exchange detailing the appointment, reappointment, dismissal, and early retirement of outside directors (사외이사). It provides names, dates of appointment and resignation, roles, and biographies. This clearly falls under announcements of changes in the company’s board of directors or senior management, matching the Board/Management Information category.
2025-09-26 Korean
[기재정정]주주총회소집공고
AGM Information Classification · 95% confidence The document is a detailed notice and correction regarding the convening of a shareholders' meeting (주주총회소집공고) for Prestige Biologics Co., Ltd. It includes agenda items for the meeting such as election of audit committee members, amendments to the articles of incorporation, and other shareholder meeting related information. It also contains detailed information about candidates for outside directors, their qualifications, and board activities. The document is dated around September 2025 and references the 11th regular shareholders' meeting. The content is focused on the announcement and correction of the shareholders' meeting notice, including agenda and procedural details, rather than the meeting materials or minutes themselves. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or related notices. The document is lengthy and substantive but is primarily a notice and correction of the AGM agenda and related information, not a full annual report or financial statement. Therefore, the best classification is AGM Information (AGM-R).
2025-09-25 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 85% confidence The document is a disclosure of a single sales and supply contract with detailed terms (contract amount, counterpart, period, payment conditions). It is not a financial report (e.g., 10-K, IR) nor an earnings release or investor presentation. It is also not an insider dealing or share issuance. It is a routine regulatory announcement of a material contract. Therefore, it falls into the fallback category “Regulatory Filings (RNS).”
2025-09-22 Korean
사업보고서 (2025.06)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Prestige Biologics, covering the fiscal period from July 1, 2024, to June 30, 2025. It includes the independent auditor's opinion, financial statements (balance sheet, income statement, etc.), and detailed notes. While it contains financial data, it is a standalone audit report prepared by an accounting firm (Samduk Accounting Corp) rather than a full 10-K annual report or a quarterly report. Therefore, it fits the 'Audit Report / Information' (AR) category. FY 2025
2025-09-19 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from Prestige Biologics titled 'Submission of Audit Report' (감사보고서 제출). It provides the audit opinion (unqualified/proper), key financial data, and details regarding the audit process. While it contains financial data, it is a formal notification of the audit report submission to the regulatory body (KRX), fitting the definition of an Audit Report/Information (AR) filing as it provides the results of the audit and the auditor's opinion. FY 2025
2025-09-18 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.